ArticleDiscover oncology2026
A bibliometric and visualization analysis of global trends and emerging themes in acetylation research for lung cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcetylation, a critical epigenetic modification, plays a central role in regulating gene expression, chromatin accessibility, protein function, and tumor progression. In lung cancer, aberrant acetylation has been implicated in processes such as metastasis, immune evasion, and therapy resistance. Despite growing scientific interest, a comprehensive bibliometric evaluation of research on acetylation in lung cancer has not yet been conducted. This study aims to systematically explore global research trends, collaboration networks, influential contributors, and emerging thematic hotspots in acetylation-related lung cancer research over the past 25 years, offering strategic insight into both foundational mechanisms and translational opportunities.
methodsA total of 917 English-language publications from 2000 to 2025 were retrieved from the Web of Science Core Collection (WoSCC). Bibliometric analyses were performed using VOSviewer, CiteSpace, Scimago Graphica, and Charticulator. Key metrics such as publication growth, country and institutional contributions, author impact, keyword co-occurrence, and citation bursts were examined to map the knowledge structure and research frontiers.
resultsThe annual number of publications and citations has increased significantly, particularly after 2015. China and the United States are the leading contributors, with Chinese institutions dominating in volume and U.S. scholars exhibiting greater citation influence. Major research clusters focus on histone deacetylases, EMT, immune regulation, and non-apoptotic cell death pathways including ferroptosis and autophagy. Recent studies emphasize the potential of combining acetylation-targeting agents with immunotherapies and nanomedicine to overcome resistance and enhance therapeutic efficacy.
conclusionAcetylation has become a pivotal regulatory mechanism and therapeutic target in lung cancer research. This bibliometric study reveals evolving hotspots and interdisciplinary linkages, highlighting the need for deeper mechanistic studies, international collaboration, and the integration of epigenetic strategies into precision oncology. The findings provide a valuable reference for future basic and translational research in lung cancer epigenetics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.